[{"id":"a2dce45d-64bf-4128-876e-4a25b3b1a037","acronym":"","url":"https://clinicaltrials.gov/study/NCT01059786","created_at":"2021-01-18T04:10:26.425Z","updated_at":"2024-07-02T16:35:06.574Z","phase":"Phase 2","brief_title":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia","source_id_and_acronym":"NCT01059786","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD22 • IL2RA • ITGAE • ITGAX • ISG20","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD22 • IL2RA • ITGAE • ITGAX • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • pentostatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 12/15/2022","primary_completion_date":" 12/15/2022","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-01"},{"id":"9ee14615-2219-4b64-beee-b0a3fb7501ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT00571662","created_at":"2021-02-17T12:52:43.145Z","updated_at":"2024-07-02T16:35:31.868Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant","source_id_and_acronym":"NCT00571662","lead_sponsor":"University of Nebraska","biomarkers":" HLA-B","pipe":"","alterations":" ","tags":["HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclosporin A microemulsion • pentostatin • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 12/08/2000","start_date":" 12/08/2000","primary_txt":" Primary completion: 12/30/2008","primary_completion_date":" 12/30/2008","study_txt":" Completion: 12/30/2008","study_completion_date":" 12/30/2008","last_update_posted":"2023-10-24"},{"id":"0d3ee8f5-d80e-4d1b-9490-6b52ff00aad7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00816413","created_at":"2021-07-05T16:06:13.151Z","updated_at":"2024-07-02T16:35:40.198Z","phase":"Phase 1/2","brief_title":"Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer","source_id_and_acronym":"NCT00816413","lead_sponsor":"University of Nebraska","biomarkers":" HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(5q) • Chr del(7q)","tags":["HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclosporin A microemulsion • pentostatin • cyclosporine • ondansetron intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2008","start_date":" 09/01/2008","primary_txt":" Primary completion: 02/01/2010","primary_completion_date":" 02/01/2010","study_txt":" Completion: 02/01/2010","study_completion_date":" 02/01/2010","last_update_posted":"2023-08-14"},{"id":"a06f8976-07ab-403a-b4d1-63d88700423a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00074282","created_at":"2021-01-18T00:11:47.065Z","updated_at":"2024-07-02T16:35:44.331Z","phase":"Phase 2","brief_title":"Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL","source_id_and_acronym":"NCT00074282","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" CD5 • CD2","pipe":"","alterations":" ","tags":["CD5 • CD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • Campath (alemtuzumab) • pentostatin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 102","initiation":"Initiation: 04/14/2005","start_date":" 04/14/2005","primary_txt":" Primary completion: 12/09/2017","primary_completion_date":" 12/09/2017","study_txt":" Completion: 05/06/2018","study_completion_date":" 05/06/2018","last_update_posted":"2023-06-29"},{"id":"5f33b52c-f869-48bf-bc7e-d225940640d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT00096161","created_at":"2021-01-18T00:17:58.402Z","updated_at":"2024-07-02T16:36:50.637Z","phase":"Phase 2","brief_title":"Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant","source_id_and_acronym":"NCT00096161","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclosporin A microemulsion • pentostatin"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 05/01/2003","start_date":" 05/01/2003","primary_txt":" Primary completion: 02/01/2015","primary_completion_date":" 02/01/2015","study_txt":" Completion: 08/01/2015","study_completion_date":" 08/01/2015","last_update_posted":"2020-01-31"},{"id":"7e505bbd-4775-429f-ab0f-d06f0ac707f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00602836","created_at":"2021-01-18T02:14:12.579Z","updated_at":"2024-07-02T16:36:50.942Z","phase":"Phase 2","brief_title":"Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT00602836","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • CCND1 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • cyclophosphamide • pentostatin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 02/01/2008","start_date":" 02/01/2008","primary_txt":" Primary completion: 12/01/2010","primary_completion_date":" 12/01/2010","study_txt":" Completion: 09/12/2017","study_completion_date":" 09/12/2017","last_update_posted":"2020-01-27"},{"id":"78316ab0-ca27-4841-8b3c-30534afe4786","acronym":"","url":"https://clinicaltrials.gov/study/NCT01362790","created_at":"2021-01-18T05:34:37.494Z","updated_at":"2024-07-02T16:36:59.049Z","phase":"Phase 1/2","brief_title":"SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma","source_id_and_acronym":"NCT01362790","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • MSLN","pipe":" | ","alterations":" EGFR mutation • MSLN expression • ALK translocation","tags":["ALK • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MSLN expression • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • pentostatin • SS1(dsFv)-PE38 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 05/11/2011","start_date":" 05/11/2011","primary_txt":" Primary completion: 08/03/2016","primary_completion_date":" 08/03/2016","study_txt":" Completion: 08/07/2017","study_completion_date":" 08/07/2017","last_update_posted":"2019-06-06"},{"id":"155f14b0-469c-45ed-80bd-2fe82acb9cc0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01024010","created_at":"2021-01-18T04:00:59.484Z","updated_at":"2024-07-02T16:37:06.781Z","phase":"Phase 2","brief_title":"Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT01024010","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • CCND1 • IGH • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CCND1 • IGH • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Arzerra (ofatumumab) • pentostatin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 82","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 05/01/2013","primary_completion_date":" 05/01/2013","study_txt":" Completion: 09/28/2017","study_completion_date":" 09/28/2017","last_update_posted":"2018-09-18"},{"id":"fdc507d0-755f-4c09-bf49-649c6f8e28f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00923845","created_at":"2021-01-18T03:34:37.540Z","updated_at":"2024-07-02T16:37:17.437Z","phase":"Phase 2","brief_title":"Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer","source_id_and_acronym":"NCT00923845","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • CD4 • FOXP3 • GATA3","pipe":"","alterations":" ","tags":["CD8 • CD4 • FOXP3 • GATA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • temsirolimus • sirolimus • pentostatin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 03/01/2008","start_date":" 03/01/2008","primary_txt":" Primary completion: 06/01/2015","primary_completion_date":" 06/01/2015","study_txt":" Completion: 06/22/2017","study_completion_date":" 06/22/2017","last_update_posted":"2017-09-29"},{"id":"f2bd643d-599e-4be8-9f75-5fb1d7bb3e6a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00816595","created_at":"2021-01-18T03:06:13.407Z","updated_at":"2024-07-02T16:37:21.000Z","phase":"Phase 2","brief_title":"Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT00816595","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • CCND1 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Rituxan (rituximab) • cyclophosphamide • pentostatin • Neulasta (pegfilgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 11/29/2016","study_completion_date":" 11/29/2016","last_update_posted":"2017-06-15"},{"id":"5c5e97c0-4f73-4509-98bd-2a742ec3a840","acronym":"","url":"https://clinicaltrials.gov/study/NCT01681563","created_at":"2021-01-18T07:17:09.017Z","updated_at":"2025-02-25T13:17:55.127Z","phase":"Phase 2","brief_title":"Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT01681563","lead_sponsor":"Niguarda Hospital","biomarkers":" CD20 • CD79B • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD79B • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Arzerra (ofatumumab) • pentostatin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 11/01/2015","primary_completion_date":" 11/01/2015","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2016-12-28"},{"id":"1b2e8431-9f10-45a2-a26c-91128c40e12e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00254163","created_at":"2021-01-18T00:51:43.086Z","updated_at":"2024-07-02T16:37:27.788Z","phase":"Phase 3","brief_title":"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients","source_id_and_acronym":"NCT00254163","lead_sponsor":"US Oncology Research","biomarkers":" CD20 • CD5","pipe":"","alterations":" ","tags":["CD20 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • fludarabine IV • pentostatin"],"overall_status":"Completed","enrollment":" Enrollment 184","initiation":"Initiation: 12/01/2003","start_date":" 12/01/2003","primary_txt":" Primary completion: 09/01/2011","primary_completion_date":" 09/01/2011","study_txt":" Completion: 09/01/2011","study_completion_date":" 09/01/2011","last_update_posted":"2016-11-03"}]